ADARx Pharmaceuticals, Inc. ADRX
Set alert
As of Nov 3, 2:04 PM ET
- YTD
- -15.48%
- 1 year
- -15.48%
- Open
- 15.78
- Prev close
- 15.76
- Mkt cap
- 1.81B
- Vol
- 235.08K
- Avg vol
- 691.66K
- EPS
- -1.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.00
- High
- 16.46
- Forward P/E
- -10.42
- Beta
- 0.00
- Short ratio
- 2.00
- Inst. own
- 46.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.21
- 200-d avg
- 18.21
- 1y target
- 34.25
Key statistics
- Market cap
- 1.75B
- Enterprise value
- 1.75B
- Trailing P/E
- 0.00
- Forward P/E
- -10.42
- PEG ratio
- 0.00
- Price / sales
- 284.84
- Price / book
- 0.00
- EPS (TTM)
- -1.16
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 6.13M
- Revenue growth
- 258.70%
- Free cash flow
- 0
- Total cash
- 427.25M
- Total debt
- 6.90M
- Return on equity
- 0.00%
- Shares outstanding
- 110.74M
- Short % of float
- 0.00%
- 50-day average
- 18.21
- 200-day average
- 18.21
Analyst view
Consensus: strong buy
- Target (low)
- 32.00
- Target (mean)
- 34.25
- Target (high)
- 38.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.36348.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 2, 2026 | Sep 30, 2026 | — | -2.27 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | TD Cowen | init | — | Buy |
| Oct 20, 2026 | JP Morgan | init | — | Overweight |
| Oct 20, 2026 | UBS | init | — | Buy |
| Oct 20, 2026 | Morgan Stanley | init | — | Overweight |
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adarx.com
News
- JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38
- This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35
- Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32
- ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
- First Look: Disney Layoffs, Apple Smart Home Launch, Goldman CEO Talks
- ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
Your note
Sign in to keep a note on ADRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director | Purchase | Sep 27, 2026 | 0 |
| GEORGE SIMEON J. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| LAV BIOSCIENCES FUND V LP | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 27, 2026 | 0 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| SR ONE CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Laurion Capital Management, LP | 0.02% | 20,000 | 315.20K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 3.18% | 3,246,801 | 51.17M | Sep 29, 2026 |
| American Funds-SmallCap World Fund | 0.08% | 85,500 | 1.35M | Sep 29, 2026 |